PitchSend

Investor Presentaiton

12 Potential Headwinds & Tailwinds Headwind Tailwind Generic business continues facing negative pricing environment Increased consolidation among the US distribution supply chains More and faster ANDA approvals leading to quicker price erosion ■Fewer small molecule blockbuster drugs invented ■Impact of patent linkage and patent term extension in Taiwan ■ Pipeline of complex generics benefits from a faster approval cycle and higher margins ■ CRAMS grow faster than the pharma ■ Pharmerging markets are expected to grow due to increasing geriatric population and healthcare expenditure ScinoPharm

View entire presentation